Table 4
Predicted five-year observed conditional survival proportion given selected time already survived, by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 2013 to 2017


Table 4
Predicted five-year observed conditional survival proportion given selected time already survived, by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 2013 to 2017
Table summary
This table displays the results of Predicted five-year observed conditional survival proportion given selected time already survived. The information is grouped by Diagnostic group / subgroup (appearing as row headers), Time already survived (years), 0, OCSP (%), 1, 3, 5, 10 and 95% CI (appearing as column headers).
Diagnostic group / subgroup Time already survived (years)
0 OCSP (%) 1 OCSP (%) 3 OCSP (%) 5 OCSP (%) 10
OCSP (%) 95% CI 95% CI 95% CI 95% CI
from to from to from to from to
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 88 93 91 94 98 97 98 98 97 99 99 98 100
a. Lymphoid leukemias 93 95 94 97 98 97 99 99 98 99 99 98 100
b. Acute myeloid leukemias 65 79 72 85 95 88 98 97 92 99 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
c. Chronic myeloproliferative diseases 90 93 83 97 92 80 97 95 82 99 96 72 99
II. Lymphomas and reticuloendothelial neoplasms 92 95 93 97 97 95 98 99 97 99 100 98 100
a. Hodgkin lymphomas 99 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 84 89 83 93 93 87 96 96 90 98 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
c. Burkitt lymphoma 94 97 87 99 98 87 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
d. Miscellaneous lymphoreticular neoplasms 94 98 93 100 99 94 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
III. CNS and miscellaneous intracranial and intraspinal neoplasms 72 85 82 88 94 92 96 96 93 97 97 95 99
a. Ependymomas and choroid plexus tumour 78 81 70 88 89 78 95 88 74 94 97 82 100
b. Astrocytomas 82 93 89 95 99 97 100 99 97 100 99 97 100
c. Intracranial and intraspinal embryonal tumours 71 84 77 89 91 84 95 92 84 96 92 85 96
d. Other gliomas 42 65Note E: Use with caution 53 74 92 81 96 95 86 98 98 85 100
IV. Neuroblastoma and other peripheral nervous cell tumours 84 86 81 90 89 85 93 95 91 97 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
a. Neuroblastoma and ganglioneuroblastoma 84 86 81 90 90 85 93 95 91 97 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
V. Retinoblastoma 94 94 85 98 99 92 100 99 92 100 99 91 100
VI. Renal tumours 96 97 92 98 98 94 99 98 94 99 99 95 100
a. Nephroblastoma and other nonepithelial renal tumours 96 98 94 99 99 95 100 99 95 100 99 94 100
VII. Hepatic tumours 72Note E: Use with caution 86Note E: Use with caution 71 93 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
VIII. Malignant bone tumours 72 73 65 79 90 83 95 93 87 97 99 94 100
a. Osteosarcomas 65 67Note E: Use with caution 55 76 87 75 94 91 79 96 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
c. Ewing tumour and related sarcomas of bone 79 78Note E: Use with caution 66 87 92 79 97 95 83 99 98 84 100
IX. Soft tissue and other extraosseous sarcomas 70 77 71 82 92 87 95 98 94 99 99 94 100
a. Rhabdomyosarcomas 69 75 65 82 92 85 96 99 92 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
d. Other specified soft tissue sarcomas 71 79 68 87 90 78 95 95 84 98 97 83 100
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 91 99 94 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 99 93 100
b. Malignant extracranial and extragonadal germ cell tumours 91 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 95 69 99
c. Malignant gonadal germ cell tumours 97 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
XI. Other malignant epithelial neoplasms and malignant melanomas 92 95 90 98 98 94 99 99 95 100 98 93 100
b. Thyroid carcinomas 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
f. Other and unspecified carcinomas 88 89 77 95 93 80 98 97 83 100 97 82 100
XII. Other and unspecified malignant neoplasms 80Note E: Use with caution 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 98 85 100
.. not available for a specific reference period
E Use with caution
Notes: OCSP = observed conditional survival proportion; CI = confidence interval; CNS = central nervous system. Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry. All estimates are based on invasive behaviour cases only. Five-year observed conditional survival represents the probability of surviving an additional five years. The use of caution is suggested in the interpretation of estimates associated with an unrounded standard error > 0.05 and ≤ 0.10.
Source: Statistics Canada, Canadian Cancer Registry death linked file (1992 to 2017).

More information

ISSN: 1209-1367

Note of appreciation

Canada owes the success of its statistical system to a long-standing partnership between Statistics Canada, the citizens of Canada, its businesses, governments and other institutions. Accurate and timely statistical information could not be produced without their continued co-operation and goodwill.

Standards of service to the public

Statistics Canada is committed to serving its clients in a prompt, reliable and courteous manner. To this end, the Agency has developed standards of service which its employees observe in serving its clients.

Copyright

Published by authority of the Minister responsible for Statistics Canada.

© Her Majesty the Queen in Right of Canada as represented by the Minister of Industry, 2021

All rights reserved. Use of this publication is governed by the Statistics Canada Open Licence Agreement.

Catalogue no. 82-003-X

Frequency: Monthly

Ottawa

Report a problem on this page

Is something not working? Is there information outdated? Can't find what you're looking for?

Please contact us and let us know how we can help you.

Privacy notice

Date modified: